Conatus Pharma

Conatus Pharmaceuticals, Inc. is a biotechnology company that focuses on the development and commercialization of novel medicines to treat chronic diseases. The firm engages in developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease and is designed to reduce the activities of human caspases. It also develops CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways. The company was founded by Alfred P. Spada, Jennifer Giottonini Cayer, and Steven J. Mento on July 13, 2005 and is headquartered in San Diego, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

London, United Kingdom--(Newsfile Corp. - August 7, 2023) - Charles Karsten's family-office consortium, Conatus Global, opens doors to deals by bringing startups and investors face to face. Two world-renowned venture capitalists recently led a lucrative Series A funding round for a pioneering neuroscience company, brought to their notice through Karsten's offices.

Conatus Global Opens the Door for Lucrative Funding from Top Tier Venture Capitalists

SAN DIEGO, May  14, 2020  (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on HST 004, its patented, naturally-derived material for spinal disc repair in the Journal of Medicine and Surgical Sciences.

Histogen Publishes Preclinical Data on its HST 004 Spinal Disc Program

SAN DIEGO, May  11, 2020  (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for HST 001, the Company’s lead therapeutic candidate for the treatment of androgenic alopecia in men.

Histogen Receives US FDA IND Approval to Initiate Phase 1b/2a Trial of HST 001 in Androgenic Alopecia

SAN DIEGO, May  07, 2020  (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today convened and adjourned its special meeting of stockholders in order to obtain a quorum and specific stockholder approvals required pursuant to the terms of its merger agreement with Histogen Inc.

The Conatus Pharmaceuticals Special Meeting of Stockholders Seeking Approval for Proposed Merger with Histogen Inc. will Reconvene on May 21, 2020

SAN DIEGO, April  20, 2020  (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today that it has submitted an Investigational Device Exemption (IDE) application with the U.S. Food and Drug Administration (FDA) for the initiation of a Phase 1 clinical trial of HST 002 for the treatment of facial folds and wrinkles.

Histogen Announces Investigational Device Exemption Application for HST 002

SAN DIEGO, April  15, 2020  (GLOBE NEWSWIRE) -- Histogen Inc., a regenerative medicine company with a novel biological platform that replaces and regenerates tissues in the body, announced today the publication of data on its human extracellular matrix (hECM) for cartilage regeneration in the Journal of Orthopaedic and Trauma Care.

Histogen Publishes New Preclinical Data on its HST 003 Orthopedic Program

Proposed Merger Creates Regenerative Medicine Company with Three Clinical-stage Product Candidates and  Combined Company Capitalization Expected to Support Operations into 2021

Conatus Pharmaceuticals and Histogen Enter into Definitive Merger Agreement

Allergan

CymaBay Therapeutics

Galmed Pharmaceuticals

Intercept Pharma

Madrigal Pharmaceuticals

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

NASH Scorecard Year to Date: The Winners and the Losers

SAN DIEGO, Nov.  18, 2019  (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional independent member.

Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates

Conatus (CNAT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Conatus (CNAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Conatus (CNAT) Upgraded to Strong Buy: Here's What You Should Know

Conatus' (CNAT) earnings and revenues surpass estimates in the second quarter. However, the company stalls the development of its lead candidate emricasan.

Conatus (CNAT) Beats on Q2 Earnings, Stops Emricasan Studies

Conatus (CNAT) delivered earnings and revenue surprises of 83.33% and 54.16%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Conatus Pharmaceuticals (CNAT) Reports Q2 Loss, Tops Revenue Estimates

Will Conatus Pharmaceuticals (CNAT) Report Negative Q2 Earnings? What You Should Know

Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.

Conatus' Emricasan Lags Primary Goal in Liver Function Study

Shares of micro-cap biotech Conatus Pharmaceuticals Inc (NASDAQ: CNAT) were sinking further into penny stock territory Tuesday after two announcements made Monday after the market close.

NASH Disappointment Forces Conatus To Explore Strategic Alternatives

Conatus (CNAT) reported earnings 30 days ago. What's next for the stock?

Conatus (CNAT) Down 5.8% Since Last Earnings Report: Can It Rebound?

Conatus' (CNAT) lead candidate, emricasan, developed for treating patients with fibrosis or cirrhosis caused by NASH misses the primary endpoint in two mid-stage studies that hits the stock massively.

Conatus Down More Than 60% in the Past 90 Days: Here's Why

Conatus, (CNAT) earnings and revenues lag estimates in the first-quarter of 2019. Emricasan remains in focus.

Conatus' (CNAT) Earnings, Revenues Miss Estimates in Q1

Conatus (CNAT) delivered earnings and revenue surprises of -16.67% and -15.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Conatus Pharmaceuticals (CNAT) Reports Q1 Loss, Lags Revenue Estimates

Conatus Pharmaceuticals (CNAT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Why Is Conatus (CNAT) Down 37.8% Since Last Earnings Report?

Gilead Sciences

Merck

Novartis

NASH is a highly lucrative market with blockbuster potential. Let us take a look at the winners and losers in this space so far in 2019.

NASH Scorecard So Far This Year: A Look at the Hits & Misses

Conatus' (CNAT) stock plunges as the phase IIb study on emricasan for the treatment of biopsy-confirmed NASH and liver fibrosis fails.

News for Conatus Pharma Stock (CNAT)